The global market for shotgun metagenomics clinical reporting is poised for significant growth, driven by the increasing use of advanced genomic testing in healthcare for diagnosing infectious diseases. According to a report by ResearchAndMarkets.com, the market is expected to expand from $1.58 billion in 2025 to $1.83 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%1. By 2030, the market is projected to reach $3.4 billion, with a CAGR of 16.7%2.
This growth is largely attributed to advancements in next-generation sequencing technologies and a heightened demand for diagnostics during infectious disease outbreaks. Increased funding for microbiology and clinical genomics research has also played a crucial role in supporting market expansion. The development of molecular testing infrastructure in hospital laboratories and a growing awareness of the importance of monitoring antimicrobial resistance have further accelerated the adoption of shotgun metagenomics clinical reporting.
Key drivers of market growth include the broader adoption of precision medicine and personalized diagnostics, the increasing use of artificial intelligence in genomic data interpretation, and the development of decentralized and point-of-care sequencing systems. There is also a rising demand for rapid pathogen detection in critical care settings and for cloud-based bioinformatics platforms that facilitate efficient clinical workflows.
Trends shaping the shotgun metagenomics clinical reporting market include AI-powered pathogen detection, automated clinical interpretation, cloud-based genomic data sharing, and ultra-rapid sequencing for point-of-care infectious disease testing. Integrated genomic analytics for predicting antimicrobial resistance and decentralized sequencing systems for hospital-based metagenomic testing are expected to influence market dynamics through 2030.
The prevalence of infectious diseases is a major factor propelling market growth. Increased global connectivity and population movement have led to more frequent disease outbreaks, necessitating faster and more comprehensive diagnostic methods. Shotgun metagenomics clinical reporting can identify pathogens, antimicrobial resistance markers, and co-infections directly from clinical samples, enabling healthcare providers to make more accurate diagnoses and select targeted treatments.
According to the World Health Organization, there were approximately 8.2 million new tuberculosis diagnoses in 2023, up from 7.5 million in 2022, marking a 9.3% increase3. This underscores the ongoing burden of infectious diseases and the need for advanced clinical diagnostic technologies that support timely treatment decisions.
Innovation in the market is increasingly focused on respiratory genomic testing and the analysis of microbial cell-free DNA from clinical fluids. In April 2025, Karius Inc. launched Karius Focus BAL, a metagenomic sequencing test designed to analyze bronchoalveolar lavage fluid. This test can identify over 500 pathogens and deliver diagnostic results within one day of sample receipt. It has demonstrated the ability to detect 50% more causes of infectious pneumonia than conventional testing methods, highlighting the potential of advanced metagenomic diagnostics for vulnerable patient populations.
Strategic partnerships are also enhancing access to infectious disease testing. In April 2026, Karius Inc. partnered with Mayo Clinic Laboratories to offer the Karius Spectrum and Karius Focus | BAL tests through Mayo Clinic Laboratories. This collaboration aims to improve access to comprehensive pathogen detection and clinical reporting, thereby supporting the broader adoption of advanced metagenomic testing.
In 2025, North America led the shotgun metagenomics clinical reporting market, benefiting from established healthcare infrastructure, genomic research capabilities, and the early adoption of advanced molecular diagnostics. The Asia-Pacific region is expected to experience the fastest growth during the forecast period. The market analysis covers regions including Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries analyzed in the market include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
The market is segmented by product type (software and services), sample type (blood, stool, respiratory, cerebrospinal fluid, tissue biopsy, urine, and other body fluids), sequencing technology type (short read, long read, and hybrid sequencing), application type (infectious disease diagnostics, oncology, microbiome analysis, antimicrobial resistance, and other applications), and end-user type (hospitals and clinics, diagnostic laboratories, research institutes, and others).
Footnotes:
- The market is projected to grow from $1.58 billion in 2025 to $1.83 billion in 2026, representing a CAGR of 16.4%. Source.
- The market is forecast to reach $3.4 billion by 2030, expanding at a CAGR of 16.7%. Source.
- According to the World Health Organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, compared with 7.5 million in 2022. Source.
Featured Image: Megapixl @ Ipopba